Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAP4K3 | Q8IVH8 | 3/20 | 0.45 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 8/20 | 0.40 |
| ▸ | FGFR2 | P21802 | 8/20 | 0.40 |
| ▸ | FGFR3 | P22607 | 8/20 | 0.40 |
| ▸ | MET | P08581 | 1/20 | 0.39 |
| ▸ | GRK5 | P34947 | 2/20 | 0.38 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.38 |
| ▸ | KDR | P35968 | 2/20 | 0.38 |
| ▸ | GRK2 | P25098 | 1/20 | 0.38 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.37 |
| ▸ | CSF1R | P07333 | 2/20 | 0.37 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.37 |
| ▸ | HRH1 | P35367 | 1/20 | 0.37 |
| ▸ | TTK | P33981 | 1/20 | 0.37 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29907113 | 1.00 | MAP4K3 (0.45) | MAP4K3ALKKCNH2FGFR1FGFR2 | |
| SCHEMBL23210853 | 0.93 | FGFR1 (0.37) | MAP4K3ALKKCNH2FGFR1FGFR2 | |
| SCHEMBL29907024 | 0.93 | FGFR1 (0.37) | MAP4K3ALKKCNH2FGFR1FGFR2 | |
| SCHEMBL29907014 | 0.89 | MAP4K3 (0.43) | MAP4K3ALKKCNH2FGFR1FGFR2 | |
| SCHEMBL23210923 | 0.89 | MAP4K3 (0.43) | MAP4K3ALKKCNH2FGFR1FGFR2 | |
| SCHEMBL23211097 | 0.89 | CYP2D6 (0.39) | MAP4K3FGFR1FGFR2FGFR3MET | |
| SCHEMBL23211090 | 0.89 | CYP2D6 (0.35) | MAP4K3METCYP2D6HRH1TTK | |
| SCHEMBL29907190 | 0.87 | MET (0.43) | FGFR1FGFR2FGFR3METFGFR4 | |
| SCHEMBL23211019 | 0.87 | MET (0.43) | FGFR1FGFR2FGFR3METFGFR4 | |
| SCHEMBL23264135 | 0.86 | RET (0.39) | FGFR1FGFR2FGFR3METFGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2025-02-20 | — | — | US | disclosed |
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2024-09-10 | — | — | US | disclosed |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2023-10-26 | — | — | US | disclosed |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | INCYTE CORPORATION (US) | 2023-03-21 | — | — | US | disclosed |
| EP-4045151-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | Incyte Corporation (US) | 2022-08-24 | — | — | EP | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| WO-2021076602-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION (US) | 2021-04-22 | — | — | WO | disclosed |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | INCYTE CORPORATION | 2021-04-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12083124-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | MAP4K3 1210/4885ALK 28/4885KCNH2 4166/4885 |
| US-20210106588-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAP4K3 1210/4885ALK 28/4885KCNH2 4166/4885 |
| US-20250057852-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAP4K3 1210/4885ALK 28/4885KCNH2 4166/4885 |
| US-11607416-B2 | Bicyclic heterocycles as FGFR inhibitors | FGFR1, FGFR3, FGFR2 | MAP4K3 1210/4885ALK 28/4885KCNH2 4166/4885 |
| US-20230338389-A1 | BICYCLIC HETEROCYCLES AS FGFR INHIBITORS | FGFR1, FGFR3, FGFR2 | MAP4K3 1210/4885ALK 28/4885KCNH2 4166/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.